ArticleJournal of natural medicines2026
Alcoholic extract of Salvia castanea Diels f. tomentosa Stib. ameliorates hypobaric hypoxia-induced right ventricular hypertrophy by inhibiting the P53-SAT1-ALOX15 pathway and up-regulating the SLC7A11-GPX4 pathway.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Salvia castanea Diels f. tomentosa Stib. (SCD) is a traditional Tibetan herbal medicine that is frequently employed in the treatment of cardiovascular disease. However, the mechanism of its effect on plateau hypoxia-induced right ventricular hypertrophy remains unclear. In the present study, we evaluated the antihypoxic effect of the alcoholic extract of Salvia castanea Diels f. tomentosa Stib. (SCDA) through a normal pressure hypoxia tolerance experiment in mice, and investigated the effect and possible mechanism of SCDA on hypoxia-induced right ventricular hypertrophy in rats. 0.3 and 0.6 g/kg SCDA were used to treat Sugen5416 + hypoxia-induced right ventricular hypertrophy in SD rats for 3 weeks. The findings indicated that SCDA (0.6 g/kg) could inhibit right ventricular hypertrophy, as evidenced by a reduction in heart weight/body weight, Fulton's index, mean pulmonary artery pressure and hypertrophic markers. Furthermore, through network pharmacology in conjunction with transcriptomics and molecular docking as well as experimental validation, it was demonstrated that SCDA reduced lipid peroxidation products, mainly through inhibiting hypoxia-induced activation of the tumour proteins p53 (P53), spermine/ spermine N1 acetyltransferase 1 (SAT1) and arachidonate 15-lipoxygenase (ALOX15). Similarly, SCDA also increased levels of the antioxidant glutathione (GSH), which is associated with inhibition of P53 and promotion of the expression of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), resulting in an improved balance between antioxidant and oxidant systems. This provides new drugs and targets for the treatment of right ventricular hypertrophy.
Indexed as
Identifiers
41291181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.